Nisa Investment Advisors LLC Sells 20,529 Shares of DexCom, Inc. $DXCM

Key Points

• Nisa Investment Advisors reduced its stake in DexCom by 53.4%, selling 20,529 shares in Q4 and leaving 17,919 shares valued at about $1.19 million.
• Quarterly results beat expectations: DexCom reported $0.68 EPS vs. $0.65 expected and $1.26B revenue (up 13.1% YoY), and analysts hold a "Moderate Buy" consensus with an average target of $86.50.
• High institutional ownership and insider activity: institutions own 97.75% of the stock, insiders own 0.32%, and EVP Michael Jon Brown recently sold 1,700 shares at about $64.85 each.

Nisa Investment Advisors LLC reduced its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 53.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,919 shares of the medical device company's stock after selling 20,529 shares during the period. Nisa Investment Advisors LLC's holdings in DexCom were worth $1,189,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in DXCM. Fulcrum Capital LLC increased its stake in shares of DexCom by 3.2% in the fourth quarter. Fulcrum Capital LLC now owns 41,086 shares of the medical device company's stock worth $2,727,000 after buying an additional 1,267 shares during the period. Brookstone Capital Management purchased a new stake in DexCom during the 4th quarter valued at $276,000. J. Safra Sarasin Holding AG boosted its position in DexCom by 57.9% during the 4th quarter. J. Safra Sarasin Holding AG now owns 36,283 shares of the medical device company's stock valued at $2,408,000 after buying an additional 13,299 shares during the period. Mn Services Vermogensbeheer B.V. grew its holdings in DexCom by 4.8% in the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 153,677 shares of the medical device company's stock worth $10,200,000 after acquiring an additional 7,077 shares during the last quarter. Finally, ORG Partners LLC grew its holdings in DexCom by 124.3% in the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company's stock worth $34,000 after acquiring an additional 281 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Stock Performance

NASDAQ:DXCM opened at $62.22 on Friday. The firm has a market capitalization of $23.95 billion, a P/E ratio of 29.63, a PEG ratio of 1.21 and a beta of 1.55. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The company's 50-day simple moving average is $69.11 and its 200 day simple moving average is $67.14.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, beating analysts' consensus estimates of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter last year, the firm earned $0.45 earnings per share. The business's revenue for the quarter was up 13.1% on a year-over-year basis. As a group, analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. BTIG Research reaffirmed a "buy" rating and set a $85.00 price objective on shares of DexCom in a research note on Monday, March 9th. Robert W. Baird set a $87.00 target price on DexCom in a research note on Friday, February 13th. Morgan Stanley restated an "overweight" rating on shares of DexCom in a report on Monday, January 12th. Weiss Ratings raised DexCom from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, March 4th. Finally, Evercore upgraded DexCom from an "in-line" rating to an "outperform" rating and set a $90.00 price objective for the company in a report on Tuesday, March 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $86.50.

Insiders Place Their Bets

In related news, EVP Michael Jon Brown sold 1,700 shares of the firm's stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $64.85, for a total transaction of $110,245.00. Following the completion of the transaction, the executive vice president owned 112,904 shares of the company's stock, valued at $7,321,824.40. This trade represents a 1.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.32% of the stock is currently owned by company insiders.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.